Comparative Pharmacology
Head-to-head clinical analysis: HALOPERIDOL LACTATE versus THIOTHIXENE HYDROCHLORIDE INTENSOL.
Head-to-head clinical analysis: HALOPERIDOL LACTATE versus THIOTHIXENE HYDROCHLORIDE INTENSOL.
HALOPERIDOL LACTATE vs THIOTHIXENE HYDROCHLORIDE INTENSOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Haloperidol lactate is a typical antipsychotic that exerts its effects primarily by blocking dopamine D2 receptors in the brain, particularly in the mesolimbic and mesocortical pathways. It also has antagonistic activity at alpha-1 adrenergic receptors and limited affinity for serotonin receptors.
Thiothixene is a typical antipsychotic that blocks postsynaptic dopamine D1 and D2 receptors in the central nervous system, particularly in the mesolimbic and mesocortical pathways. It also has affinity for serotonin 5-HT2, histamine H1, and alpha-1 adrenergic receptors, contributing to its therapeutic and adverse effects.
2-5 mg intramuscularly or intravenously every 4-8 hours for acute agitation. Maximum 20 mg/day.
Initial: 2 mg orally three times daily. Maintenance: 15-30 mg orally daily in divided doses. Maximum: 60 mg/day.
None Documented
None Documented
14–26 hours (terminal elimination half-life); may be prolonged in hepatic impairment or with repeated dosing due to accumulation.
Terminal elimination half-life ranges from 26 to 36 hours in healthy adults, allowing for once-daily dosing in maintenance therapy. In chronic use, the half-life may be prolonged due to accumulation.
Renal (approximately 40% as metabolites, <1% as unchanged drug); fecal (approximately 15%); remainder metabolized with unknown fate.
Primarily renal and biliary; about 50-60% of a single dose is excreted in the urine as metabolites and unchanged drug within 48 hours, with approximately 30-40% eliminated in feces via biliary secretion. Less than 1% of the parent drug is excreted unchanged in urine.
Category A/B
Category C
Typical Antipsychotic
Typical Antipsychotic